RESUMEN
We have genotyped 657 Norwegian men, including 282 lung cancer patients (147 non-operable and 135 operable) and 375 healthy referents (210 smokers and 165 non-smokers), to study the possibility that glutathione S-transferase M1 (GSTM1)-null and/or N-acetyl transferase 2 (NAT2)-slow genotypes confer susceptibility towards lung cancer in smokers. Compared with smoking referents, there was a significant over-representation of the GSTM1-null genotype among patients with squamous cell carcinoma (SQ) [odds ratio (OR) = 1.7, 95% confidence interval (95%CI) = 1.1-2.7], and the NAT2-slow genotype among patients with large cell carcinoma or mixed histological diagnosis (LM) (OR = 2.5, 95%CI = 1.0-6.1). In contrast to operable patients, non-operable patients showed a clear over-representation of slow genotypes if they were younger (= 63 years; versus older: OR = 3.9, 95%CI = 1.7-8.8) or younger light smokers [= 30 pack-years (PY); versus heavy smokers: OR = 5.7, 95%CI = 1.4-23.3]. Among younger light smokers, the slow genotype appeared to be associated with an increased risk of developing non-operable tumours only (OR = 6.3, 95%CI = 1.9-20.4), especially other types of tumours than SQ (OR = 10.8, 95%CI = 1.4-83.9). The null genotype (OR = 3.9, 95%CI = 1.1-13.5) and the null/slow combination (OR = 4.5, 95%CI = 1.5-13.8) seemed to increase the risk for non-operable SQ only. These results are supported by logistic regressions of patients allowing interactions between tumour type (or treatment) and PY (or age), and indicate that the GSTM1-null genotype could be an important susceptibility factor for SQ while the NAT2-slow genotype may have an impact on other types of lung cancer. Individuals with the GSTM1-null and/or NAT2-slow genotypes may constitute susceptible groups with increased risk to contract non-operable lung cancer at younger age and lower smoking dose.
Asunto(s)
Glutatión Transferasa/genética , Isoenzimas/genética , Neoplasias Pulmonares/etiología , Polimorfismo Genético , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Arilamina N-Acetiltransferasa/genética , Genotipo , Humanos , Neoplasias Pulmonares/enzimología , Neoplasias Pulmonares/genética , Masculino , Persona de Mediana Edad , Fumar/efectos adversosRESUMEN
The cytochrome P450 enzyme debrisoquine 4-hydroxylase metabolizes many different classes of commonly used drugs, such as antidepressants and neuroleptics. Deficient hydroxylation of debrisoquine, known as the poor metabolizer (PM) phenotype, affects 5-10% of Caucasians and may lead to adverse reactions upon administration of drugs in standard doses. This autosomal recessive metabolic deficiency is caused by the possession of two PM-associated mutations in the human CYP2D6 gene locus coding for the enzyme. These mutations include at least four different single base mutations and two different large gene deletion alleles. The single base mutations can be rapidly detected by PCR methods. In contrast, the large gene deletions have so far only been directly identified by RFLP analysis. By the use of sequence data previously published by others, we report here an alignment of different CYP2D alleles to focus on the presence of almost completely identical sequences immediately downstream of both CYP2D7 and CYP2D6 which may seriously complicate and interfere with PCR-based detection of the gene deletion. Based on this analysis, we have developed a rapid assay which, for the first time, detects the 13kb (also called 11.5 kb) Xba I gene deletion allele by the use of long-PCR technology. The primers were designed to amplify a 3.5 kb PCR product in the presence of this D6(D) allele. We have evaluated the method on 23 different DNA samples heterozygous (n = 22) or homozygous (n = 1) for the 13 kb gene deletion allele (previously typed by RFLP analyses). All samples were correctly identified by the assay. The PCR method did not detect the rare 11 kb Xba I gene deletion allele (n = 5), and there was no false positive amplification from deletion negative DNA samples (n = 47). This sensitive and specific PCR-based assay for detection of the D6(D) allele will improve the scientific and clinical use of CYP2D6 genotyping.
Asunto(s)
Sistema Enzimático del Citocromo P-450/genética , Eliminación de Gen , Oxigenasas de Función Mixta/genética , Reacción en Cadena de la Polimerasa/métodos , Polimorfismo de Longitud del Fragmento de Restricción , Alelos , Secuencia de Bases , Citocromo P-450 CYP2D6 , Sistema Enzimático del Citocromo P-450/metabolismo , ADN/genética , Cartilla de ADN , Desoxirribonucleasas de Localización Especificada Tipo II , Inglaterra , Genotipo , Humanos , Hidroxilación , Oxigenasas de Función Mixta/metabolismo , Datos de Secuencia Molecular , Noruega , Fenotipo , Mapeo Restrictivo , Población Blanca/genéticaRESUMEN
Genotyping of five CYP2D6 alleles (wt, A,B,D,E) has been performed in 218 lung cancer patients and 289 healthy controls. PCR-methods were used to determine the CYP2D6A and CYP2D6B alleles. Both patients and controls were of Caucasian Norwegian origin. In the lung cancer group all major histological types were represented. The frequency of the CYP2D6B allele which is associated with poor metabolizers (PM), was 0.235 in the lung cancer population and 0.200 in the control population. The frequencies of the CYP2D6A allele, another mutant allele associated with the PM-phenotype, were 0.007 and 0.013 in the lung cancer and control population respectively. RFLP analysis using the restriction enzyme Xba I to determine the D and E alleles, was also performed on 178 of the patients and on 118 of the controls. The frequency of the deletion variant CYP2D6D (13 kb) was 0.025 in the lung cancer group and 0.012 in the control group. None of these frequencies in the lung cancer patients were statistically significantly different from the frequencies of the control population. When combining the PCR-typing results (CYP2D6A, CYP2D6B) 20 individuals were found to carry two PM-associated alleles in the lung cancer group (n = 204) compared with only six among the controls (n = 117). This corresponds to a PM frequency of 9.8% in the lung cancer population compared with 5.1% in the control population which is, however, not significantly different from each other. These results are not in concordance with previous results which suggest that the EM-phenotype is a susceptibility marker for lung cancer.
Asunto(s)
Carcinoma/epidemiología , Sistema Enzimático del Citocromo P-450/genética , Neoplasias Pulmonares/epidemiología , Pulmón/enzimología , Oxigenasas de Función Mixta/genética , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Secuencia de Bases , Carcinoma/enzimología , Carcinoma/genética , Distribución de Chi-Cuadrado , Citocromo P-450 CYP2D6 , Susceptibilidad a Enfermedades , Femenino , Marcadores Genéticos , Variación Genética , Genotipo , Humanos , Neoplasias Pulmonares/enzimología , Neoplasias Pulmonares/genética , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Noruega/epidemiología , Fumar , Población Blanca/genéticaRESUMEN
We have examined restriction fragment length polymorphisms of the H-ras-1 gene in germ-line DNA from 214 lung cancer patients and 309 unaffected controls. When DNA samples were digested with MspI/HpaII, Southern blot analysis revealed at least 22 different alleles, grouped according to their frequencies as common, intermediate, and rare. The frequency of rare alleles in lung cancer patients (16/428) is significantly different (p = 0.002) from that in the control group (5/618). Individuals with rare alleles were found to be at 4.7-fold greater risk of lung cancer than those with no rare alleles.
Asunto(s)
ADN de Neoplasias/genética , Genes ras/genética , Neoplasias Pulmonares/genética , Alelos , Humanos , Noruega , Polimorfismo de Longitud del Fragmento de Restricción , Secuencias Repetitivas de Ácidos Nucleicos/genéticaRESUMEN
In this study of 221 lung cancer patients and 212 controls, no association between a Msp I polymorphism in the CYP1A1 gene and an increased risk of lung cancer was found. Histological type, smoking habits and family history were also examined. No associations between the Msp I restriction fragment length polymorphism in the CYP1A1 gene and any of these parameters were found. These results are in contrast to a previous report by a Japanese group (Kawajiri et al., 1990) who found an association between the less common allele and an increased susceptibility to lung cancer in their population. The frequency of the less common Msp I 1.9 kb fragment allele (C2) appears to be three times greater in the Japanese population than in the Norwegian population and a Caucasian population of North America. It is possible that in the Asian population this Msp I polymorphism is in linkage disequilibrium with another mutation important for CYP1A1 gene expression, whereas in the Caucasian population these mutations are in equilibrium.
Asunto(s)
Sistema Enzimático del Citocromo P-450/genética , Neoplasias Pulmonares/epidemiología , Neoplasias Pulmonares/genética , Polimorfismo de Longitud del Fragmento de Restricción , Adenocarcinoma/enzimología , Adenocarcinoma/epidemiología , Adenocarcinoma/genética , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Southern Blotting , Carcinoma/enzimología , Carcinoma/epidemiología , Carcinoma/genética , Carcinoma de Células Pequeñas/enzimología , Carcinoma de Células Pequeñas/epidemiología , Carcinoma de Células Pequeñas/genética , Carcinoma de Células Escamosas/enzimología , Carcinoma de Células Escamosas/epidemiología , Carcinoma de Células Escamosas/genética , ADN/sangre , ADN/genética , ADN/aislamiento & purificación , Sondas de ADN , Desoxirribonucleasa HpaII , Desoxirribonucleasas de Localización Especificada Tipo II , Femenino , Genotipo , Humanos , Neoplasias Pulmonares/enzimología , Masculino , Persona de Mediana Edad , Noruega/epidemiología , Valores de Referencia , FumarRESUMEN
We have examined DNA restriction fragment length polymorphisms (RFLP) of the Ha-ras-1 gene in DNA from 118 lung cancer patients and 123 unaffected controls. When DNA samples were digested with MspI/HpaII restriction endonucleases. Southern blot analysis demonstrated 4 common, 4 intermediate and 7 different rare alleles in the combined population after hybridization to the pGDa1 probe. Six of the rare alleles were unique for the lung cancer group and 1 rare allele for the control group. The frequency of rare alleles in lung cancer patients (10/236) was significantly different (P less than 0.01) from the control group (1/246). The lung cancer group also had a significantly lower frequency of the common 2.57 kb fragment than the controls (P less than 0.02). The results thus indicate that Ha-ras genotyping may be of value in lung cancer risk assessment.
Asunto(s)
Alelos , Genes ras , Neoplasias Pulmonares/genética , Southern Blotting , Sondas de ADN , ADN de Neoplasias/genética , Genotipo , Humanos , Polimorfismo de Longitud del Fragmento de RestricciónRESUMEN
We studied 83 lung cancer patients and 129 controls for the EcoRI polymorphism of the L-myc gene. No association was found between the L-myc RFLP and increased risk of metastasis, either to lymph nodes or metastasis to other organs. There was no difference in survival time between the three different genotypes. The S-allele of the L-myc RFLP has been correlated to increased metastasis in lung cancer. We found no tendency towards a higher frequency of this allele in the cohort of patients with positive family history compared to the patients with no known first degree relatives with cancer. A higher frequency of the S-allele in the adenocarcinomas compared to other histological groups was found, although this difference was not statistically significant. No difference in the gene frequency of the L-myc RFLP was found between the lung cancer patients and the normal controls. These results are in contrast with a previous report. Possible explanations for the discrepancies are discussed.
Asunto(s)
Alelos , Neoplasias Pulmonares/genética , Metástasis de la Neoplasia/genética , Oncogenes , Polimorfismo de Longitud del Fragmento de Restricción , Adenocarcinoma/genética , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Células Pequeñas/genética , Carcinoma de Células Escamosas/genética , Femenino , Genotipo , Humanos , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana EdadRESUMEN
The effects of chloroquine, verapamil and monensin on secretion of very-low-density lipoproteins (VLDLs) were studied in cultured rat hepatocytes. Maximum inhibition of VLDL-triacylglycerol secretion by 50-90% of control was reached at 200 microM chloroquine, 200 microM verapamil and 5 microM monensin, whereas no effect on cellular triacylglycerol synthesis was observed. The inhibition could be seen within 15 min and was reversible after washout of the drugs. Chloroquine and verapamil inhibited both cellular protein synthesis and protein secretion, whereas monensin reduced protein secretion without any effect on protein synthesis. Control experiments with cycloheximide revealed that intact protein synthesis was not necessary for secretion of VLDL-triacylglycerol during 2 h. Electron micrographs of cells treated with chloroquine, verapamil or monensin showed swollen Golgi cisternae containing VLDL-like particles. By morphometry, a more than 2-fold increase in volume fractions and size indices of Golgi complexes and secondary lysosomes was observed, except that monensin had no significant effect on these parameters of secondary lysosomes. These results suggest that the inhibition of VLDL secretion by chloroquine, verapamil and monensin which takes place in the Golgi complex might be due to disruption of trans-membrane proton gradients. An increase in pH of acidic Golgi vesicles may cause swelling and disturb sorting and membrane flow through this organelle.